SCHEMBL24257821

SCHEMBL24257821

COc1c(C(=O)O)ncc(Oc2ccccc2)c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.44
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
NUDT1 P36639 1/20 0.39
TRPC6 Q9Y210 2/20 0.38
RAB9A P51151 1/20 0.38
BRD4 O60885 1/20 0.38
KDM4E B2RXH2 2/20 0.38
FYN P06241 1/20 0.38
POLB P06746 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CSNK2A2 P19784 1/20 0.37
CSNK2A1 P68400 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
TSPO P30536 1/20 0.37
RAF1 P04049 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid Methyl Ester SCHEMBL29248911 0.84 CTNNB1 (0.40) TTRKMT2AMEN1NUDT1RAB9A
SCHEMBL24257589 0.81 EGLN1 (0.48) KMT2ABRD4
SCHEMBL4446942 0.75 TTR (0.51) TTRKMT2AMEN1RAB9AKDM4E
SCHEMBL24257762 0.74 CNR2 (0.43) KMT2AMEN1POLBSMN1; SMN2
SCHEMBL24257791 0.74 PTPN1 (0.49) BRD4CYP2C9CYP2C19SMN1; SMN2TDP1
SCHEMBL30546848 0.74 ALDH1A1 (0.38) KMT2AMEN1POLBTDP1
SCHEMBL24257758 0.74 POLB (0.41) KMT2AMEN1RAB9AFYNPOLB
SCHEMBL24257708 0.74 ALDH1A1 (0.38) KMT2AMEN1POLBTDP1
SCHEMBL26260299 0.72 HSD17B10 (0.41) KDM4EFYNHSD17B10
SCHEMBL27437578 0.71 KMT2A (0.43) KMT2ATRPC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 TTR 3197/4885KMT2A 868/4885MEN1 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.